Home » Posts tagged 'exercise of warrants' (Page 2)

Tag Archives: exercise of warrants

Ananda Developments #ANA – Exercise of Warrants

 

ana

Ananda announces that 16,863 ordinary shares of 0.2p each in the Company (“Ordinary Shares”) have been issued following the exercise of warrants at 0.45p per share.

Application will be made for the new Ordinary Shares to be admitted to trading on the Access segment of the AQSE Growth Market and admission is expected to become effective on Tuesday, 11 January 2022.

Following this issue, the Company has 797,579,590 Ordinary Shares in issue, each share carrying the right to one vote.

This figure of 797,579,590 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

Power Metal Resources #POW – Exercise of Warrants

 

Power Metal Resourcpowes plc (LON:POW) the London listed exploration company seeking large-scale metal discoveries across its global project portfolio announces an exercise of warrants and warrant update.

Warrant Exercise

The Company has received notices to exercise warrants over 16,000,000 new ordinary shares of 0.1 pence each in the Company (“Warrant Shares”) raising an additional £112,000 for the Company.

The Warrant Shares are being issued pursuant to the exercise of 16,000,000 warrants at an exercise price of 0.7 pence per ordinary share of 0.1 pence each in the Company (“Ordinary Share”).

Warrant Update

The warrants exercised above were issued in December 2019 pursuant to a Power Metal financing (“2019 Warrants”) and had a 17 December 2021 expiry.

Following the exercise of the 2019 Warrants announced today the Company can confirm that, excluding those held by current Power Metal directors, all warrants due for expiry in December 2021 have been exercised in full.

As noted above Power Metal directors hold the remaining 11,250,000 2019 Warrants which remain to be exercised, subject to the Company dealing code. This includes 6,250,000 2019 Warrants held by Paul Johnson (Chief Executive Officer) and 5,000,000 2019 Warrants held by Ed Shaw (Non-executive Director).

Application will be made for the 16,000,000 Warrant Shares to be admitted to trading on AIM which is expected to occur on or around 21 December 2021 (“Admission”). The Warrant Shares will rank pari passu in all respects with the ordinary shares of the Company currently traded on AIM.

Following Admission, the Company’s issued share capital will comprise 1,441,839,987 ordinary shares of 0.1p each. This number will represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.

 

For further information please visit https://www.powermetalresources.com/ or contact:

Power Metal Resources plc

Paul Johnson (Chief Executive Officer)

+44 (0) 7766 465 617

SP Angel Corporate Finance (Nomad and Joint Broker)

Ewan Leggat/Charlie Bouverat

+44 (0) 20 3470 0470

SI Capital Limited (Joint Broker)

Nick Emerson                                                                                                           

+44 (0) 1483 413 500

First Equity Limited (Joint Broker)

David Cockbill/Jason Robertson

+44 (0) 20 7330 1883

 

Power Metal Resources #POW – Exercise of Warrants

pow

Power Metal Resources plc (LON:POW) the London listed exploration company seeking large-scale metal discoveries across its global project portfolio announces it has received a notice to exercise warrants over 1,500,000 new ordinary shares of 0.1 pence each in the Company (“Warrant Shares”) raising an additional £10,500 for the Company.

The Warrant Shares are being issued pursuant to the exercise of 1,500,000 warrants at an exercise price of 0.7 pence per ordinary share of 0.1 pence each in the Company (“Ordinary Share).

ADMISSION AND TOTAL VOTING RIGHTS

Application will be made for the 1,500,000 Warrant Shares to be admitted to trading on AIM which is expected to occur on or around 9 November 2021 (“Admission”). The Warrant Shares will rank pari passu in all respects with the ordinary shares of the Company currently traded on AIM.

Following Admission, the Company’s issued share capital will comprise 1,343,339,987 ordinary shares of 0.1p each. This number will represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.

Advanced Oncotherapy (AVO) – Exercise of Warrants and issue of Shares

AVO1Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 14,000 new ordinary shares of 1p in the Company at a price of 6 pence per New Share pursuant to the exercise of 14,000 warrants.

Application has been made for the 14,000 Shares to be admitted to trading on AIM and it is expected that Admission will occur on or about 21 April 2016. The Shares will rank pari passu in all aspects with the existing ordinary shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 1,418,342,375 ordinary shares, with voting rights. The Company does not hold any ordinary shares in treasury. Therefore the total number of ordinary shares in the Company with voting rights will be 1,418,342,375. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact:

Advanced Oncotherapy Plc

www.avoplc.com

Michael Sinclair, Chief Executive Officer

Tel: +44 20 3617 8728

Nicolas Serandour, Chief Operating and Financial Officer

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.